




| <p>PTO-1449 REPRODUCED </p> | | | ATTORNEY DOCKET NO. CEN0250 | APPLICATION NO. 09/920,137 | | |
|---|------------------|----------|-----------------------------------|-------------------------------|---------------|----------------------------------|
| | | | APPLICANT: George Heavner, et al. | | | |
| | | | FILING DATE August 1, 2001 | GROUP <i>1647</i> | | |
| U. S. PATENT DOCUMENTS | | | | | | |
| EXAM- INER INI- TIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB- CLASS | FILING DATE IF APPROPRIATE |
| <i>SS</i> | AA 4,603,106 | 07/29/86 | Cerami et al. | 435 | 7 | |
| | AB 4,822,776 | 04/18/89 | Cerami et al. | 514 | 21 | |
| | AC 5,231,024 | 7/27/93 | Moeller et al. | 435 | 240.27 | |
| | AD 5,342,613 | 08/30/94 | Creaven et al. | 424 | 85.1 | |
| | AE 5,658,570 | 08/19/97 | Newman et al. | 424 | 184.1 | |
| | AF 5,656,272 | 12/12/97 | Le, et al. | 424 | 133.1 | |
| | AG 5,698,195 | 12/16/97 | Le, et al. | 424 | 133.1 | |
| | AH 5,750,105 | 5/12/98 | Newman et al. | 424 | 133.1 | |
| | AI 5,888,511 | 03/30/99 | Skurkovich et al. | 424 | 145.1 | |
| | AJ 5,919,452 | 07/06/99 | Le, et al. | 424 | 133.1 | |
| | AK 5,958,413 | 09/28/99 | Anagnostopoulos et al. | 424 | 178.1 | |
| | AA2 5,993,833 | 11/30/99 | DeLacharriere et al. | 424 | 401 | |
| | AB2 6,190,691 B1 | 02/20/01 | Mak | 424 | 449 | |
| | AC2 6,277,969B1 | 08/21/01 | Le, et al. | 536 | 23.1 | |
| <i>AS</i> | AD2 6,284,471B1 | 09/04/01 | Le, et al. | 435 | 7.1 | |
| FOREIGN PATENT DOCUMENTS | | | | | | |
| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB- CLASS | TRANSLATION YES NO |
| <i>AS</i> | AL 0212489B1 | 03/04/87 | EPO | | | |
| | AM 0218868 | 04/22/87 | EPO | | | |
| | AN 0260610B1 | 03/23/88 | EPO | | | |
| <i>AS</i> | AO 0288088B1 | 10/26/88 | EPO | | | |
| EXAMINER <i>G. Seto</i> | | | DATE CONSIDERED | <i>12/22/03</i> | | |

| PTO-1449 REPRODUCED  INFORMATION DISCLOSURE CITATION IN AN APPLICATION JUN 17 2002 <small>PATENT & TRADEMARK OFFICE</small> | | ATTORNEY DOCKET NO. CEN0250 | | APPLICATION NO. 09/920,137 | |
|---|---------------------|-----------------------------------|---------------------------------|-------------------------------|-----------|
| | | APPLICANT: George Heavner, et al. | | | |
| | | FILING DATE August 1, 2001 | | GROUP <i>(64)</i> | |
| FOREIGN PATENT DOCUMENTS | | | | | |
| | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS |
| <i>15</i> | AP 0308378B1 | 22 MAR 89 | EPO | | |
| | AQ 0350690A2 | 17 JAN 90 | EPO | | |
| | AL2 0351789B1 | 24 JAN 90 | EPO | | |
| | AM2 WO90/00902 | 08 FEB 90 | PCT | | |
| | AN2 0380068A1 | 01 AUG 90 | EPO | | |
| | A02 0393438A2 | 24 OCT 90 | EPO | | |
| | AP2 0398327B1 | 22 NOV 90 | EPO | | |
| | AQ2 0412486B1 | 13 FEB 91 | EPO | | |
| | AL3 WO91/02078 | 21 FEB 91 | PCT | | |
| | AM3 0486526B2 | 07 MAR 91 | EPO | | |
| | AN3 0433900A1 | 26 JUN 91 | EPO | | |
| | A03 WO91/09967 | 11 JUL 91 | PCT | | |
| | AP3 WO92/16553 | 19 MAR 92 | PCT | | |
| | AQ3 WO92/07076 | 30 APR 92 | PCT | | |
| | AL4 0 526 905 A3 | 07 AUG 92 | EPO | | |
| | AM4 WO92/11383 | 09 JUL 92 | PCT | | |
| | AN4 WO92/13095 | 06 AUG 92 | PCT | | |
| | A04 WO93/02108 | 04 FEB 93 | PCT | | |
| | AP4 0526905A3 | 10 FEB 93 | EPO | | |
| | AQ4 AU-B-17649/92 | 23 MAY 96 | AU | | |
| | ALS EP 0 610 210 B1 | 16 MAY 01 | EPO | | |
| EXAMINER <i>gse</i> | | | DATE CONSIDERED <i>12/22/03</i> | | |

| | | | |
|---|-----|---|-------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION ON AN APPLICATION JUN 17 2002 PATENT & TRADEMARK OFFICE | | ATTORNEY DOCKET NO. CEN0250 | APPLICATION NO. 09/920,137 |
| | | APPLICANT George Heavner, et al. | |
| | | FILING DATE August 1, 2001 | GROUP 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | AR | Beutler, B. et al., "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," <i>Nature</i> , 316:552-554 (1985). | |
| | AS | Beutler, B. et al., "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," <i>Science</i> , 229:869-871 (1985). | |
| | AT | Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," <i>Science</i> , 229:1202-1207 (1985). | |
| | AU | Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985). | |
| | AV | Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985). | |
| | AW | Paulus, H., Preparation and Biomedical Applications of Bispecific Antibodies, <i>Behring Inst. Mitt.</i> , No.78:118-132 (1985). | |
| | AX | Hayashi, H. et al., "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," <i>Recent Adv. Chemother.</i> , 820-821 (1985). | |
| | AY | Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. & Biophys. Res. Comm.</i> , 137(2):847-854 (1986). | |
| | AZ | Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987). | |
| | AR2 | Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987). | |
| | AS2 | Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987). | |
| | AT2 | Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987). | |
| | AU2 | Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987). | |
| | AV2 | Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987). | |
| EXAMINER JG | | DATE CONSIDERED | 12/22/03 |

| | | | |
|--|-----------------------------|---|-------------------------------|
| PTO-1449 REPRODUCED  | | ATTORNEY DOCKET NO. CEN0250 | APPLICATION NO. 09/920,137 |
| | | APPLICANT George Heavner, et al. | |
| | | FILING DATE August 1, 2001 | GROUP 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| | AW2 | Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988). | |
| | AX2 | Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988). | |
| | AY2 | Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988). | |
| | AZ2 | Sunahara, N. et al., "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor . and its antibodies using a bacterial cell wall carrier," <i>J Immunol Methods</i> , 109:203-214 (1988). | |
| | AR3 | Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society, Abstract</i> 184, p. 50 (1989). | |
| | AS3 | Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor α Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989). | |
| | AT3 | Whittle, Nigel, et al., "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," <i>J. Cell Biochem, Supl.</i> 13A:96 (1989). | |
| | AU3 | Duncombe, Andrew S. et al., "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," <i>J Immunol</i> , 143:3828-3834 (1989). | |
| | AV3 | Aderka, Dan et al., "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," <i>J Immunol</i> , 143:3517-3523 (1989). | |
| | AW3 | Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor-. at 2.6 \square Resolution," <i>J Biol Chem</i> , 264:17595-17605 (1989). | |
| | AX3 | Gillies, Stephen D. et al., "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," <i>J Immunol Methods</i> , 125:191-202 (1989). | |
| | AY3 | Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989). | |
| | AZ3 | Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989). | |
| EXAMINER  | DATE CONSIDERED 12/22/03 | | |

| | | | |
|--|-----|--|-------------------------------|
| PTO-1449 REPRODUCED INTERNATIONAL DISCLOSURE CITATION IN AN APPLICATION JUN 17 2002 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE | | ATTORNEY DOCKET NO. CEN0250 | APPLICATION NO. 09/920,137 |
| | | APPLICANT George Heavner, et al. | |
| | | FILING DATE August 1, 2001 | GROUP 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 18 | AR4 | Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 β and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989). | |
| | AS4 | Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, <i>Abstracts of Annual Meeting 1989</i> . | |
| | AT4 | Kameyama, Koh-zoh, et al., "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," <i>FEBS Lett.</i> , 244:301-306 (1989). | |
| | AU4 | Genebank Accession, No. N90300 (1989, November 1). | |
| | AV4 | Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990). | |
| | AW4 | Tavernier, Jan et al., "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," <i>J. Mol. Biol.</i> , 211:493-501 (1990). | |
| | AX4 | Lucas, R. et al., "Generation and characterization of a neutralizing rat anti-rm TNF- α monoclonal antibody," <i>Immunology</i> , 71:218-223 (1990). | |
| | AY4 | Hinshaw, L.B. et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)," <i>Circulatory Shock</i> , 30:279-292 (1990). | |
| | AZ4 | Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990). | |
| | AR5 | Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990). | |
| | AS5 | Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990). | |
| | AT5 | Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990). | |
| | AU5 | Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E ₂ Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990). | |
| 18 | AV5 | Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990). | |
| EXAMINER <i>G. Heavner</i> | | DATE CONSIDERED <i>12/22/03</i> | |

| | | | |
|--|-----|---|-------------------------------|
| PTO-1449 REPRODUCED  INFORMATION DISCLOSURE CITATION IN AN APPLICATION | | ATTORNEY DOCKET NO. CEN0250 | APPLICATION NO. 09/920,137 |
| | | APPLICANT George Heavner, et al. | |
| | | FILING DATE August 1, 2001 | GROUP 1647 |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | |
| 8 | AW5 | Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990). | |
| | AX5 | Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," <i>Sem Immunol</i> , 2:457-466 (1990). | |
| | AY5 | Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990). | |
| | AZ5 | Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990). | |
| | AR6 | Von Asmuth, E.J.U. et al., "Tumour Necrosis Factor Alpha (TNF- α) and Interleukin 6 in a Zymosan-Induced Shock Model," <i>Scand. J. Immunol.</i> , 32:313-319 (1990). | |
| | AS6 | Herve, P. et al., "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, <i>Lymphoma Res.</i> 9:591 (1990). | |
| | AT6 | Silva, Ayona T. et al., "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor- α in Experimental Gram-Negative Shock," <i>J. of Infectious Diseases</i> , 162:421-427 (1990). | |
| | AU6 | Opal, Steven M. et al., "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with <i>Pseudomonas aeruginosa</i> ," <i>J. of Infectious Diseases</i> , 161:1148-1152 (1990). | |
| | AV6 | Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," <i>Clin Immunol Immunopathol</i> , 55:157-170 (1990). | |
| | AW6 | Starnes, H. Fletcher, Jr., et al., "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal <i>Escherichia Coli</i> Infection and Lethal Tumor Necrosis Factor Challenge in Mice," <i>J Immunol</i> , 145:4185-4191 (1990). | |
| | AX6 | Genebank Accession, No. M32046 (1990, June 15). | |
| ↓ | AY6 | Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991). | |
| 185 | AZ6 | Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, <i>Endotoxemia & Sepsis Conference</i> (1991). | |
| EXAMINER  | | DATE CONSIDERED 12/22/03 | |

| | | |
|---|-------------------------------------|-------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION | ATTORNEY DOCKET NO. CEN0250 | APPLICATION NO. 09/920,137 |
| <i>O I P E</i> JUN 17 2002 SC55-3074 | APPLICANT George Heavner, et al. | FILING DATE August 1, 2001 |
| | | GROUP 643. |



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

1422(0)



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

| | | |
|-----------------------------|--|--|
| SUBMISSION UNDER MPEP 609 D | Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number | 09/920,137 August 1, 2001 George Heavner 1645 J. Schresey CEN-250 |
| Page 1 of 1 | | |

U.S. PATENT DOCUMENTS

RECEIVED

AUG 28 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner
Signature

Geels

Date
Considered

12/22/03



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Approved for use through 10/31/2002. GMB 0531-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

| | |
|-------------------------------|----------------|
| <u>Application Number</u> | 09/920,137 |
| <u>Filing Date</u> | August 1, 2001 |
| <u>First Named Inventor</u> | George Heavner |
| <u>Group Art Unit</u> | 1645 |
| <u>Examiner Name</u> | G. Scherabek |
| <u>Attorney Docket Number</u> | CEN-250 |

U.S. PATENT DOCUMENTS

RECEIVED

AUG 28 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Signature *[Signature]* **Date Considered** *12/22/03*

MPRISER-A: If the citation is not in conformance with MPRISER 600, draw line through citation if not in conformance.

1 Unique citation designation number. **2 See attached Kinds of U.S. Patent Documents.** **3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).** **4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.** **5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if applicable.** **An applicant is to place a check mark here if English language Translation is attached.**

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



AD Under the Paperwork Reduction Act of 1995, no persons are required to respond to

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2


| | |
|------------------------|------------------|
| Application Number | 09/920,137 |
| Filing Date | August 1, 2001 |
| First Named Inventor | George Heavner |
| Group Art Unit | 1649 |
| Examiner Name | J. S. Gheraseyan |
| Attorney Docket Number | CEN-250 |

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

RECEIVED

AUG 28 2002

~~TECH CENTER 1600/2900~~

| | | | |
|-----------------------|---|--------------------|----------|
| Examiner Signature |  | Date Considered | 12/22/03 |
|-----------------------|---|--------------------|----------|

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.